13F COMBINATION REPORT
Crestline Management, LP
Quarter ended Q1 2025 · Filed May 15, 2025 · Accession 0001315863-25-000400
Total Value
$63.2M
Positions
3
Other Managers
0
Confidential Omitted
No
Holdings (3)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | DENALI THERAPEUTICS INC | DNLI | 4,160,732 | $56.6M | 89.45% |
| 2 | SANA BIOTECHNOLOGY INC | SANA | 2,790,937 | $4.7M | 7.41% |
| 3 | 8X8 INC NEW | 282914100 | 990,580 | $2.0M | 3.13% |